• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

厌氧菌对美罗培南的敏感性。

Susceptibility of anaerobic bacteria to meropenem.

作者信息

Nord C E, Lindmark A, Persson I

机构信息

Department of Microbiology, Huddinge University Hospital, Karolinska Institute, Stockholm, Sweden.

出版信息

J Antimicrob Chemother. 1989 Sep;24 Suppl A:113-7. doi: 10.1093/jac/24.suppl_a.113.

DOI:10.1093/jac/24.suppl_a.113
PMID:2553656
Abstract

The activity of meropenem was determined against 350 strains of anaerobic bacteria by an agar dilution method. It was compared with those of piperacillin, cefoxitin, imipenem, clindamycin, metronidazole and chloramphenicol. Meropenem and imipenem were the most active agents tested. On the basis of these results, meropenem appears to be a promising antimicrobial agent for anaerobic infections and warrants further clinical investigation.

摘要

采用琼脂稀释法测定了美罗培南对350株厌氧菌的活性。并将其与哌拉西林、头孢西丁、亚胺培南、克林霉素、甲硝唑和氯霉素进行了比较。美罗培南和亚胺培南是测试的活性最强的药物。基于这些结果,美罗培南似乎是一种有前景的用于厌氧菌感染的抗菌药物,值得进一步进行临床研究。

相似文献

1
Susceptibility of anaerobic bacteria to meropenem.厌氧菌对美罗培南的敏感性。
J Antimicrob Chemother. 1989 Sep;24 Suppl A:113-7. doi: 10.1093/jac/24.suppl_a.113.
2
Comparative in-vitro activity of Sch 34343 and other antimicrobial agents against anaerobic bacteria.Sch 34343与其他抗菌剂对厌氧菌的体外活性比较
J Antimicrob Chemother. 1985 Jun;15 Suppl C:183-8. doi: 10.1093/jac/15.suppl_c.183.
3
Susceptibility of anaerobic bacteria to PD 131628.厌氧菌对PD 131628的敏感性。
Eur J Clin Microbiol Infect Dis. 1992 Jan;11(1):68-71. doi: 10.1007/BF01971277.
4
In vitro activity of L-627 against anaerobic bacteria.L-627对厌氧菌的体外活性。
Eur J Clin Microbiol Infect Dis. 1992 Aug;11(8):757-60. doi: 10.1007/BF01989987.
5
The growth-inhibitory properties of meropenem against anaerobes of clinical importance.美罗培南对具有临床重要性厌氧菌的生长抑制特性。
J Antimicrob Chemother. 1989 Sep;24 Suppl A:119-24. doi: 10.1093/jac/24.suppl_a.119.
6
Antimicrobial susceptibility of anaerobic bacteria in Sweden in 1983.1983年瑞典厌氧菌的抗菌药敏情况。
Scand J Infect Dis Suppl. 1984;43:44-9.
7
Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.脆弱拟杆菌群物种及其他厌氧菌对美罗培南、亚胺培南、哌拉西林、头孢西丁、氨苄西林/舒巴坦、克林霉素和甲硝唑的敏感性比较。
J Antimicrob Chemother. 1993 Mar;31(3):363-72. doi: 10.1093/jac/31.3.363.
8
In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria.比阿培南联合丝氨酸β-内酰胺酶抑制剂 RPX7009 对厌氧菌的体外活性。
Antimicrob Agents Chemother. 2013 Jun;57(6):2620-30. doi: 10.1128/AAC.02418-12. Epub 2013 Mar 25.
9
In vitro activity of meropenem (SM-7338), imipenem, and five other antibiotics against anaerobic clinical isolates.美罗培南(SM-7338)、亚胺培南及其他五种抗生素对临床厌氧菌分离株的体外活性
Diagn Microbiol Infect Dis. 1990 Jan-Feb;13(1):57-61. doi: 10.1016/0732-8893(90)90055-z.
10
Susceptibility of anaerobic bacteria to the new streptogramin RP 59500 in vitro.厌氧细菌对新型链阳性菌素RP 59500的体外敏感性
Eur J Clin Microbiol Infect Dis. 1989 Dec;8(12):1064-7. doi: 10.1007/BF01975171.

引用本文的文献

1
A ten years (2000-2009) surveillance of resistant Enterobacteriaceae in Zhejiang Province, China.中国浙江省十年(2000 - 2009年)耐碳青霉烯类肠杆菌科细菌监测
Microb Ecol Health Dis. 2012 Mar 23;23. doi: 10.3402/mehd.v23i0.11609. eCollection 2012.
2
Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.亚胺培南和美罗培南:体外活性、药代动力学、临床试验及不良反应的比较
Can J Infect Dis. 1998 Jul;9(4):215-28. doi: 10.1155/1998/831425.
3
Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.
美罗培南与亚胺培南/西司他丁治疗需要手术的腹腔内感染的对比研究
Eur J Clin Microbiol Infect Dis. 1993 Jun;12(6):449-53. doi: 10.1007/BF01967440.
4
Pharmacokinetics of meropenem in patients with intra-abdominal infections.美罗培南在腹腔内感染患者中的药代动力学。
Antimicrob Agents Chemother. 1994 Jan;38(1):151-4. doi: 10.1128/AAC.38.1.151.
5
Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.美罗培南:抗菌活性、药代动力学特性及临床疗效综述
Drugs. 1995 Jul;50(1):73-101. doi: 10.2165/00003495-199550010-00007.
6
Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.394株脆弱拟杆菌、非脆弱拟杆菌属拟杆菌种及梭杆菌属细菌对新型抗菌药物的敏感性
Antimicrob Agents Chemother. 1991 Jun;35(6):1214-8. doi: 10.1128/AAC.35.6.1214.
7
Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.美罗培南与亚胺培南-西司他丁在年轻健康男性中的药代动力学比较。
Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):85-8. doi: 10.1007/BF01964413.